LGALS3 and chronic kidney disease: Gal3 concentrations are elevated in AKI and CKD, and Gal3 inhibitors have been shown to downregulate inflammation and fibrosis in a variety of diseases (Supplementary Table S1) (Drechsler et al., 2015; Ji et al., 2017; Alam et al., 2019; Sun et al., 2021b; Kim et al., 2021; Boutin et al., 2022).